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Synopsis 
 
Over the last 10 years trilostane, a competitive inhibitor of steroid synthesis, has become 
widely used for the treatment of canine hyperadrenocorticism. Trilostane causes a significant 
but reversible decrease in cortisol production and a concomitant improvement in clinical signs 
in most dogs with this common condition. Side effects, though infrequent, can be serious: 
dogs treated with this drug require regular monitoring. This review summarises current 
knowledge of the use of this drug with particular emphasis on its efficacy, safety, adverse 
reactions and effects on endocrine parameters. Brief mention is made of its other uses in dogs 
and other species.   
 
Introduction 
 
Trilostane (4,5-epoxy-17-hydroxy-3-oxoandrostan-2-carbonitrile) is a synthetic steroid whose 
ability to reduce adrenocorticotrophic hormone (ACTH) stimulation of adrenal corticoids was 
first described 40 years ago [1]. Further studies demonstrated that it was orally active and that 
its mode of action was as a competitive inhibitor of steroid synthesis [2]. The use of trilostane 
was investigated in various human conditions, including hyperadrenocorticism (HAC), 
hyperaldosteronism and breast cancer [3-7]. Although it did appear to have some effect on 
some cases of human HAC it was not as effective as other available treatments and in a recent 
consensus statement is no longer considered as a treatment option [8]. It is, however, still used 
in the treatment of human breast cancer [9]. 
 
The first report of the use of trilostane in canine HAC was by Hurley and others (1998) who 
successfully treated a series of 15 dogs, including 2 with adrenal dependent disease [10]. In 
the following decade many other abstracts and papers have followed. Trilostane was first 
authorised in the UK in 2005 for the treatment of canine HAC but has since been authorised 
in many other countries, most recently in the US. Human and imported veterinary 
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formulations are often used in those countries were it is not currently authorised for veterinary 
use. 
 
The information contained within this paper is intended for an international audience and 
some information (e.g. doses) may be at variance with national recommendations. 
Veterinarians should consult their national regulatory authorities or local commercial 
representatives if they are unsure as to their local rules and guidelines. 
 
Mode of Action 
 
Trilostane is a competitive inhibitor of the 3β-hydroxysteroid dehydrogenase/isomerase 
system (3β-HSD), an essential enzyme system for the synthesis of several steroids including 
cortisol and aldosterone [2]. This enzyme catalyses the conversion of the 3β-hydroxysteroids 
(pregnenolone, 17-hydroxypregnenolone and dehydroepiandrosterone (DHEA)) to the 3-
ketosteroids (progesterone, 17-hydroxyprogesterone and androstenedione) (see diagram 1). 
Trilostane does not appear to have any direct hormonal activity of its own and does not 
interact with the main sex hormone receptors [11].  
 
Most studies on trilostane’s mode of action have been performed in vitro, in laboratory rats or 
in humans. There is little information on the effect of trilostane in healthy dogs. In dogs with 
HAC it has been shown that trilostane causes a significant increase in 17 
hydroxypregnenolone and DHEA concentrations [12]. These results confirmed an inhibitory 
effect of trilostane on the 3β-HSD. However, these authors also noted that 17-
hydroxyprogesterone concentrations did not change in dogs treated with trilostane despite a 
marked decrease in cortisol concentrations. They postulated that, in addition to its inhibitory 
effect on the 3β-HSD system, trilostane has an influence on the 11β-hydroxylase and possibly 
on the interconversion of cortisol and cortisone by 11β-hydrozysteroid dehydrogenase (11β-
HSD) [12]. However further studies by the same group demonstrated that cortisone 
concentrations in normal dogs are increased by ACTH [13]. This does not consistently happen 
in human beings, which suggests that the 11β-HSD enzyme in dogs is subtly different from 
the human equivalent. In addition cortisone concentrations in dogs with pituitary dependent 
HAC (PDH) are consistently increased; again this is in contrast to the situation in human 
beings [13]. Trilostane treatment reduces cortisone (both basal and following stimulation with 
ACTH) in dogs with PDH but to a lesser extent than it reduces cortisol concentrations [13]. 
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Therefore, although trilostane may have an effect on 11β-HSD, until more is known about the 
canine version of this enzyme it is not possible to say this with any certainty.   
 
Pharmacology 
 
Few pharmacokinetic studies have been performed on trilostane. In the rat and monkey 
trilostane is rapidly absorbed after oral dosing with peak blood concentrations occurring 
between 0.5-1 hour (rat) and between 2-4 hours (monkey) [14]. In human volunteers the peak 
concentrations were between 2 and 4 hours [15]. In dogs peak trilostane concentrations are 
seen within 1.5 hours and decrease to baseline values in about 18 hours (Dechra Veterinary 
Products Limited, UK, data on file). The variability exhibited in systemic levels of trilostane 
following oral administration is possibly due in part to suboptimal absorption owing to its low 
water solubility. It has been shown that feeding immediately after the administration of 
trilostane increases its absorption [16]. Trilostane is cleared from the blood after 7 hours in 
the rat, 6-8 hours in the human and 48 hours in the monkey. Following the administration of 
trilostane to rats, the metabolite ketotrilostane is formed within a few minutes [17]. 
Ketotrilostane has about 1.7 times the activity of trilostane in steroid inhibition [15]. 
Conversely, when ketotrilostane is given to rats, trilostane is rapidly formed, suggesting that 
these compounds exist in equilibrium in vivo. Trilostane and ketotrilostane are metabolised 
into any one of 4 further metabolites. Excretion in rats is mainly via faeces, whilst in monkeys 
urinary excretion is more important [14].  
 
Use in canine pituitary dependent hyperadrenocorticism 
 
The clinical use of trilostane in canine HAC, and in particular PDH, has now been evaluated 
in several published clinical studies from centres across the world [18-23]. In addition 
unpublished studies have been conducted for regulatory purposes (Dechra Veterinary 
Products; data on file). Many other studies of the specific endocrine effects of trilostane have 
also been published but insufficient clinical data is presented to assess this aspect.  Direct 
metanalysis of the combined data from these studies is not useful as the study populations 
(referral or first opinion; PDH only or all HAC), diagnostic evaluations, starting doses, 
monitoring methods, dose adjustment protocols and end points vary between the studies. 
However comparison of these published studies is worthwhile and is summarised in Table 1. 
It should be noted that some of these studies were funded, at least in part, by commercial 
sources.  
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Starting dose and frequency 
 
The starting dose of the 6 studies listed in Table 1 ranged from 0.5 mg/kg twice daily to 
20mg/kg once daily. To some extent the available formulations determined this choice. The 
finishing dose range in each study was even more variable however the mean/median dose 
was in the range 2.8 to 7.3 mg/kg in 5 of the studies (although in two of these studies the dose 
was split twice daily). It therefore seems logical therefore to recommend a starting dose the 
range 2 to 5 mg/kg per day.  
 
There are no studies which directly compare different frequencies of trilostane administration. 
Four of the studies in Table 1 used once daily dosing as the starting point [18-20, 23]. 
However it has been demonstrated that the effect of trilostane on basal and ACTH stimulated 
cortisol is considerably less than 24 hours in most cases [24]. In the same study the authors 
also documented six dogs with HAC whose clinical signs were poorly controlled and whose 
post-ACTH concentrations observed four and 24 hours after the administration of trilostane 
were always higher than the equivalent cortisol concentrations in four dogs whose clinical 
signs were controlled. When four of the poor controlled dogs were switched to twice daily 
dosing, the clinical condition of three of them improved and their cortisol responsiveness to 
ACTH stimulation was reduced after both four and 24 hours. Following the publication of 
these results two studies opted to start dogs on a twice daily regimen [21, 22]. However the 
overall results obtained in these two studies were not superior to those obtained by earlier 
studies [18-20]. It is likely that at least a few dogs require twice daily dosing with trilostane to 
achieve control; however, it is probably not necessary to divide the starting dose for all dogs.  
In one study in which trilostane was used twice daily in all dogs there was a higher rate of 
adverse incidents than in any of the other five studies in Table 1 [21].   
 
Monitoring 
 
In the 6 studies listed in Table 1 the frequency of monitoring is one of the most consistent 
features. However the basis for this frequency is not clear. The caution of the early studies 
may not be appropriate now that more is known about the response to trilostane. In particular 
the clinical signs and cortisol concentrations continue to improve in most dogs in the first 
month [18, 20]. Performing an ACTH stimulation test 10 to 14 days after starting therapy is 
likely not to be so useful as changing the dose at this stage would risk increasing the dose of 
trilostane too early. Very few cases indeed develop trilostane overdosage in the first 2 weeks 
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of therapy. A review consultation should be adequate and an ACTH stimulation test only 
performed if adverse effects have been noted. Monthly monitoring for the first 3 months 
followed by 3 monthly monitoring for the first year followed by 4 to 6 monthly monitoring 
thereafter may well be adequate.  
 
Most clinical studies to date have used the clinical signs and the ACTH stimulation test as the 
primary methods of assessing control [18-23]. In these studies trilostane caused significant 
reductions in both the mean basal and post-ACTH stimulation cortisol concentrations in dogs 
with HAC in the first month of treatment. Furthermore these improvements were also 
maintained in the study populations for the duration of the trial. However, despite its 
widespread use, the ACTH stimulation test has never been validated for trilostane therapy.  
 
The ACTH stimulation test does provide a valuable assessment of the immediate capacity of 
the adrenal glands to secrete cortisol. For drugs (such as mitotane) and diseases (such as 
immune mediated hypoadrenocorticism) that cause permanent effects on the adrenal gland the 
ACTH stimulation test provides an effective method of monitoring the adrenal gland. 
However due to the relatively short lasting effects of trilostane the ACTH stimulation test 
varies considerably with the time of testing relative to dosing [24]. Early studies of trilostane 
were often conducted without the knowledge of later studies and so the clinical effects were 
sometimes discordant to the ACTH stimulation test results. The short duration of action of 
trilostane may have a protective effect against the development of hypoadrenocorticism, as 
many dogs with no serum cortisol response to ACTH stimulation 2 – 3 hours post trilostane 
dosing, do not develop signs of hypoadrenocorticism [19]. However equally many dogs that 
have a target level post ACTH stimulation test serum cortisol will exhibit signs of HAC [20, 
24]. Various different timings and cortisol target levels for the ACTH stimulation test when 
used to monitor trilostane therapy have been used [18-23]. The lower the target range the 
greater the chance of hypoadrenocorticism. However in the earlier studies many dogs did not 
have their cortisol levels reduced to the authors stated target range [18-21]. Later studies, 
which tended to be more precise on the timing of the ACTH stimulation test, achieved a 
higher rate of success in this respect [22, 23]. 
 
Based on the data in Table 1, the author’s currently recommended target range for the post 
ACTH cortisol concentration is 40 to 120 nmol/l (1.4–4.3 mg/dl) for ACTH stimulation tests 
started 2 to 4 hours after dosing; however if dogs have a post-ACTH cortisol concentration of 
120–200 (4.3-7.2 mg/dl) and are responding well to treatment then an increase in monitoring 
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rather than dose may be more acceptable to the owners. Other methods of monitoring 
trilostane are under active investigation and are considered below.  
 
Dose changes 
 
Most of the published studies on trilostane treatment record details of the number of dose 
changes. To some extent this has to be interpreted in the light of the starting dose and the 
target range for post ACTH cortisol concentrations in an individual study. However in all 
studies a sizeable proportion of dogs required a dose increase and a small minority required a 
dose decrease. These results emphasise the importance of regular monitoring when treating a 
case of canine HAC. Even once stable dogs may become unstable at subsequent monitoring 
visits. 
 
Efficacy and Survival  
 
In the studies in Table 1 trilostane it was found to be between 67 to 100% effective in 
resolving the various signs of HAC over 3 to 6 months [18-23]. In contrast, mitotane is 
effective in about 80% of cases of PDH [27]. It is reasonable to conclude that trilostane is at 
least as effective as mitotane in controlling the clinical signs of most cases of canine HAC.  
 
There have been two studies that have compared the survival times of dogs treated with 
trilostane with those treated with mitotane [25,26]. In the first study the survival times of 148 
dogs treated for PDH were studied using clinical records from three UK veterinary centers 
[25].  Of these animals 123 (83.1%) were treated with trilostane, while 25 (16.9%) were 
treated with mitotane. The median survival time for animals treated with trilostane was 662 
days (range 8-1971) and for mitotane it was 708 days (range 33-1339). There was no 
significant difference between the survival times for animals treated with trilostane and those 
treated with mitotane (see Figure 1).  
In the second study the median survival time of forty dogs treated with trilostane twice a day 
(900 days) was significantly longer (P=0·05) than the median survival time (720 days) of 46 
dogs treated with mitotane using a non-selective adrenocorticolytic protocol [26]. Both 
protocols had similar levels of long term efficacy (75%), although short term efficacy with the 
mitotane was higher. They also had a similar prevalence of side effects (25%), although two 
of the mitotane treated dogs died. This prevalence of side effects with trilostane has not been 
recorded by others [18-23]. In those countries which do not currently regard either routine 
twice daily dosing with trilostane or non-selective adrenocorticolysis with mitotane as first 
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choice protocols this study has more relevance to animals that have failed a conventional first 
choice protocol.  
 
Safety (to humans) 
 
Trilostane does not require any special safety precautions in its handling. It is formulated in 
capsules that are now available in a range of sizes (therefore splitting or re-formulating 
capsules should not be necessary). If a capsule is accidentally damaged the drug does not 
cross the skin barrier. Ingestion or inhalation of small quantities of trilostane would be 
expected to have no effect on a human being.  If taken in large doses (which would have to be 
a deliberate action) then trilostane can act as an abortifacent and potentially could induce 
hypocortisolism. Doses of 60mg or more given 4 times daily over 4 weeks were used in ten 
healthy men with minimal effects on their adrenal function [28]. In contrast the risks of 
handling mitotane are well documented [29]. Trilostane is safer for humans to handle than 
mitotane. 
 
Safety and adverse effects in dogs 
 
One common feature of the studies in Table 1 is that trilostane appears to be well tolerated by 
almost all dogs. If the numbers of dogs from these 6 clinical trials are combined then only 39 
dogs out of 244 dogs (16%) treated with trilostane developed adverse effects which may have 
been attributable to trilostane [18-23]. This prevalence of side effects compares favourably 
with those reported with mitotane (25 to 42%) [27, 30, 31].  
 
If failure to respond is regarded as an adverse effect then it is probably the most common 
adverse effect of trilostane administration. In these cases an increase in the dose (and /or 
frequency) or a change to an alternative medication (such as mitotane) is indicated. More 
serious side effects include (in order of severity) adrenal necrosis, hypoadrenocorticism, 
hyperkalaemia and a few others. These are described below. 
 
Adrenal necrosis and hypoadrenocorticism 
 
The most serious side effect of trilostane that has been identified to date is acute adrenal 
necrosis. This has been documented in 2 case reports, one fatal and the other requiring 
permanent glucocorticoid therapy [32, 33]. It may also have been the cause of sudden death 
and sudden decreases in trilostane requirement in a few other cases [16].  Necrosis of the 
adrenal cortex can not be directly explained by the competitive inhibition of steriodogenesis. 
However adrenal necrosis also cannot be dismissed as isolated idiosyncratic reactions. 
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Varying degrees of adrenal necrosis and associated inflammation have been described in 5 out 
of 7 non-randomly selected post mortems of dogs that had been treated with trilostane [34]. 
All 7 dogs showed some degree of adrenal hyperplasia as well. In 2 of the dogs the lesions 
were sufficiently severe that they could have been associated with hypoadrenocorticism, 
however both cases had also received mitotane. In both cases and in 4 of the other dogs other 
causes of death were also definitively established. The severity of the lesions may have been 
related to the doses of trilostane used and the duration of treatment [34]. The interference 
from this study is that adrenal hyperplasia is common in trilostane treated dogs but it may also 
be associated with a low grade adrenal necrosis.   
 
The development of adrenal necrosis could be due to the hypersecretion of ACTH [34]. It has 
been demonstrated that trilostane causes an increase in ACTH concentrations [35]. This leads 
to the increase in the size of the adrenal glands that is observed in many dogs that are treated 
with trilostane [36]. Moreover it has been shown that even short periods of administration of 
ACTH can also, paradoxically, result in degeneration, focal necrosis and haemorrhage of 
human adrenal glands [37].  
 
Adrenal necrosis does not explain most of the cases of hypoadrenocorticism seen in trilostane 
treated dogs. Most cases of hypoadrenocorticism associated with trilostane recover rapidly 
following temporary cessation of the drug but continue to require the drug to control the 
clinical signs. This suggests that these cases have suffered from over dosage rather than 
adrenal necrosis [18-23]. Most affected cases have typical electrolyte changes (hyponatremia, 
hyperkalemia) typical of hypoadrenocorticism. However one case has been described which 
developed isolated hypocortisolism [33]  
 
There is also a theoretical risk that trilostane-induced adrenal hyperplasia could develop into 
adrenal tumours [34]. However no evidence for this has been published. 
 
ACTH concentrations also increase in normal dogs that are treated with trilostane [38] . This 
is associated with an increase in pituitary size (as assessed by MRI) and histological evidence 
of pituitary corticotroph hyperplasia and bilateral adrenal hyperplasia. It seems reasonable to 
assume that trilostane could result in an increase in the size of pituitary tumours but again no 
evidence for this has been published.  
 
 
Hyperkalaemia 
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Two of the 6 clinical studies in Table 1 recorded a mild increase in median serum potassium 
concentrations [19,21] . Dogs that develop hyperkalemia do not appear to have a low 
aldosterone concentration (Ramsey and Neiger, unpublished observations). The mechanism of 
action of this hyperkalemia has not been identified. Any trilostane treated dog with a mild 
increase in potassium should be checked with an ACTH stimulation test, rather than 
empirically reducing the dose. Trilostane can then be safely withheld whilst waiting for the 
results of the test.   
 
Other side effects 
 
Trilostane is associated with vomiting and diarrhoea in some dogs independently of any 
effects on cortisol levels. Successful treatment with trilostane might also lead to the 
development of previously suppressed immune mediated, inflammatory or neoplastic diseases 
however, so far, there have been no reports of these side effects. All of these are well 
described in relation to the use of mitotane and readers are referred to standard texts for 
descriptions of these side effects [27]. 
 
Use in PDH dogs with concurrent conditions 
 
Manufacturers recommend that trilostane should not be used in animals suffering from 
primary hepatic disease and/or renal insufficiency. However the basis for this 
recommendation is unclear in the published literature. It is true to say that information is not 
available on what dosage adjustment should be made in dogs with primary hepatic disease 
and/or renal insufficiency. Similarly there are no studies looking at trilostane use in dogs with 
concurrent diabetes mellitus and HAC. Currently the author does not reduce the dose of 
trilostane when treating a dog with diabetes and HAC. It seems logical to give the trilostane 
and insulin at the same frequency (i.e. either both once a day or both twice a day).  
 
Use in canine adrenal dependent hyperadrenocorticism 
 
There have been no large scale studies of the treatment of adrenal dependent HAC (ADH) in 
dogs. However trilostane does appear to work in ADH. Evidence of efficacy is provided by 
one small series and a couple of case reports [39-41]. It is not known if the dose, frequency or 
monitoring of trilostane treatment in ADH cases should be the same as PDH cases or not. 
Until more data is available it would be prudent to exercise caution when using trilostane in 
such cases.  
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Effects on other endocrine parameters 
 
Aldosterone 
 
Aldosterone secretion in dogs with untreated HAC is generally considered to be decreased 
[42, 43]. The effect of trilostane on aldosterone in dogs with HAC has been reported in 3 
studies. One study of 15 dogs suggested an increase in basal plasma aldosterone 
concentrations (PAC) with trilostane treatment [12]. In 2 other studies (of 17 and 63 dogs) 
trilostane did not appear to have a significant effect on basal plasma aldosterone 
concentrations [23, 44]. Trilostane does appear to reduce ACTH stimulated aldosterone 
concentrations in dogs with HAC [12, 44]. A reduction in both basal and ACTH stimulated 
aldosterone concentrations is also seen in mitotane treated dogs [42, 43]. In all 3 of the 
trilostane studies the observed effects on aldosterone concentrations were less pronounced 
than the effects on cortisol concentrations. 
In humans, and it is suggested in dogs, plasma rennin activity (PRA) (and specifically the 
PRA:PAC ratio) are a better indicator of mineralocorticoid deficiency than PAC alone [23]. It 
has been shown in a series of 63 dogs that PRA is increased by, and the PRA:PAC ratio is 
reduced by, trilostane therapy [23].  
 
Effect on urinary corticoid: creatinine ratio 
 
If the ACTH stimulation test only provides a measure of the short term effects on trilostane 
then there is a need to identify a test that measures the long term control of HAC. Initially it 
would appear that the urinary corticoid: creatinine ratio (UCCR) makes a logical choice. 
However an early study reported that it was not useful, although few details were given [19]. 
Another early study demonstrated that the mean UCCR did not decrease significantly with 
trilostane treatment [20]. These authors did however note that the UCCR was lower when the 
urine was collected shortly after dosing and higher when collected later. These authors felt 
that UCCR was useful for assessing the duration of effect of trilostane when collected 24 
hours after dosing when it was having least effect. However overall correlation with ACTH 
stimulation test results and clinical improvement was low in this study [20]. In a recent 
prospective study of 18 dogs that had been successfully treated with once daily trilostane 
UCCRs were monitored every 2 weeks for at least 8 weeks [45]. Although UCCRs did 
decrease compared with pre-treatment values they did not fall to below the upper limit of the 
reference range in the majority of dogs. Moreover, the UCCRs of 11 dogs that initially had 
insufficient doses of trilostane did not differ significantly from when the dosage was optimal. 
Post-ACTH cortisol concentrations did not correlate significantly with UCCRs at rechecks 
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during trilostane treatment. However UCCR could identify dogs that were being over-treated 
with trilostane with greater success. These results are similar to those achieved with mitotane 
[46-48]. 
 
However another recent study using twice daily trilostane suggested that measuring UCCR in 
a urine sample collected at home the same morning as a post-dosing ACTH stimulation test 
was carried out provided useful data with regards to the duration of effect of the trilostane 
[22]. In many respects this replaces a second (pre dosing) ACTH stimulation test being 
carried out in dogs that had failed to respond to once daily dosing as described by others [24]. 
Further research is needed to confirm these findings.  
 
Effect on haptoglobin and other acute phase proteins 
 
Glucocortiocids have been demonstrated to cause a significant increase in haptoglobin 
concentrations and haptoglobin has been assessed as a marker for good control of HAC with 
trilostane [49]. It was found that although serum haptoglobin concentrations decreased with 
trilostane therapy the concentrations did not closely relate to the degree of control of HAC as 
assessed by an ACTH stimulation test. A further study demonstrated that haptoglobin 
measurements, even when combined with other parameters such as cholesterol an/ or alkaline 
phosphatase, were only moderately informative of disease control. The study also 
demonstrated that serum amyloid A but not C-reactive protein decreased with trilostane 
therapy [50]. 
 
Effect on thyroid and parathyroid hormones 
 
Hyperadrenocorticism is associated with a reduction in thyroxine [51]. Fourteen out of 20 
dogs demonstrated an increase in thyroxine following trilostane treatment however, although 
the mean concentration increased, this increase was not found to be significant [52]. In 
contrast there was a significant increase in the mean concentrations of thyroid stimulating 
hormone with 14 out of the 20 dogs demonstrating an increase (of these 14 dogs, 10 also 
showed an increase in thyroxine concentrations). There was a significant decrease in the mean 
free thyroxine concentration (although most of the treated dogs had concentrations that were 
within the reference range). 
Hyperadrenocorticism is also associated with an increase in parathyroid hormone 
concentrations, which can be regarded as adrenal secondary hyperparathyroidism  [53]. 
Trilostane treatment has also been shown to cause a decrease in parathyroid hormone 
concentrations although many dogs do not return to normal [54]. 
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Other uses of trilostane in dogs 
 
Trilostane has been demonstrated to be effective in the treatment of alopecia X of 
Pomeranians, poodles and Alaskan malamutes which many authorities consider it to be a 
mild, slowly progressive form of pituitary dependent HAC [55, 56]. The doses used in these 
two studies were different (9 to 11 mg/kg once daily for the Pomeranians and Miniature 
poodles, 3.0 to 3.6 mg/kg once daily for the Alaskan malamutes). Two of the Pomeranians did 
not respond to this dose but did respond when the dose was increased by doubling the 
frequency of administration to twice daily [55]. The efficacy of trilostane in alopecia X is in 
marked contrast to the inconsistent and often temporary results achieved with other therapies 
such as melatonin, thyroxine and sex hormones. As the condition does not usually progress 
rapidly or cause significant other effects (such as polyuria, polyphagia) the need for, and risks 
of, therapy should be carefully discussed with owners before starting trilostane. 
In humans trilostane has been used to treat human hyperaldosteronism [6]. Although the 
effects of trilostane on aldosterone are less than on cortisol it would be possible to 
contemplate the use of trilostane in a case of canine or feline hyperaldosteronism (Conn’s 
syndrome) particularly when aldosterone antagonists such as spironolactone have not been 
effective. 
 
Trilostane in hyperadrenocorticism in other species 
 
The use of trilostane has been reported in the treatment of cats, horses and guinea pigs with 
hyperadrenocorticism [57-60]. The drug appears to have similar effects to those described in 
dogs however data is limited and caution is advisable. In addition there is one case report of 
its use in a cat with bilateral adrenal enlargement and excessive sex steroid hormone 
production [61]. 
 
Summary and future studies 
 
The introduction of trilostane has increased the options for the management of canine 
hyperadrenocorticism in many countries. The drug is safer for humans to handle than 
mitotane; it is nearly as effective as mitotane and has a lower frequency of serious adverse 
reactions.  
 
The optimal dosing interval has still to be formally determined. Studies comparing the success 
of once daily with twice daily administration will be important. Whatever the starting dose 
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and frequency, trilostane therapy still requires careful monitoring. However the ACTH 
stimulation test may be a suboptimal method to be the sole assessment of the efficacy and 
safety of trilostane.  Although to date, no better method has been identified, it is important 
that further studies are undertaken on the UCCR and other measurements of total daily 
cortisol production. The long term frequency of such monitoring should also be properly 
assessed.  
 
Trilostane does not cure hyperadrenocorticism and some cases are not well controlled by it. In 
these poorly controlled cases other therapeutic options (specifically mitotane) are indicated. 
Therefore access to, and the skills required to use, mitotane still need to be maintained within 
the veterinary profession. 
 
 
Page 13 of 21 
VCNA-SAP Ramsey August 2009 
References 
 
1. Neuman HC, Potts GO, Ryan WT, et al. Steroidal heterocycles XIII. 4a,4-epoxy-5a-
androst-2-eno(2,3-d)isoxazoles and related compounds (1970) J Med Chem 
1970;13(5):948-951 
2. Potts GO, Creange JE, Hardomg HR, et al. Trilostane, an orally active inhibitor of 
steroid biosynthesis. Steroids. 1978;32(2):257-67.  
3. Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane 
(WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab. 
1978;47(5):1042-51.  
4. Dewis P, Anderson DC, Bu'lock DE, et al. Experience with trilostane in the treatment 
of Cushing's syndrome. Clin Endocrinol (Oxf). 1983;18(6):533-40.  
5. Semple CG, Beastall GH, Gray CE, et al. Trilostane in the management of Cushing's 
syndrome. Acta Endocrinol (Copenh). 1983;102(1):107-10.  
6. Winterberg B, Vetter W, Groth H, et al. Primary aldosteronism: treatment with 
trilostane. Cardiology. 1985;72 Suppl 1:117-21.  
7. Williams CJ, Barley V, Blackledge G, et al. Multicenter study of trilostane: a new 
hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep. 
1987;71(12):1197-201.  
8. Biller BMK, Grossman AB, Stewart PM et al Treatment of adrenocorticotropin-
dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 
2008; 93(7):2454–2462 
9. Puddefoot JR, Barker S, Vinson GP. Trilostane in advanced breast cancer. Expert 
Opin Pharmacother. 2006;7(17):2413-9.  
10. Hurley K, Sturgess K, Cauvin A, et al. The use of trilostane for the treatment of 
hyperadrenocorticism in dogs. J Vet Int Med 1998;12(3):210 (Abstract)  
11. Tueni E, Devleeschouwer N, Leclercq G, et al. Endocrine effects of trilostane: in vitro 
and in vivo studies. Eur J Cancer Clin Oncol. 1987;23(10):1461-7.  
12. Sieber-Ruckstuhl NS, Boretti FS, Wenger M, et al. Cortisol, aldosterone, cortisol 
precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-
dependant hyperadrenocorticism treated with trilostane. Domest Anim Endocrinol. 
2006;31(1):63-75.  
13. Sieber-Ruckstuhl NS, Boretti FS, Wenger M, et al. Serum concentrations of cortisol 
and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism 
treated with trilostane. Vet Rec. 2008;163(16):477-81. 
Page 14 of 21 
VCNA-SAP Ramsey August 2009 
14. Baker JF, Benziger D, Chalecki BW, et al. Disposition of trilostane in the rat and 
monkey. Archives Internationales de Pharmacodynamie et de Therapie 1980;243(1):4-
16. 
15. Robinson DT, Earnshaw RJ, Mitchell R, et al. The bioavailability and metabolism of 
trilostane in normal subjects, a comparative study using high pressure liquid 
chromatographic and quantitative cytochemical assays. J Steroid Biochem. 
1984;21(5):601-5. 
16. Johnston L, Chohan A, Chapman E. Absorption of Trilostane in the Fasted and Non-
Fasted Healthy Dog. Proceedings 15th ECVIM Congress, 2005; p223 (abstract) 
17. McGee JP, Shaw PN. The pharmacokinetics of trilostane and ketotrilostane in an 
interconverting system in the rat. Pharmaceutical Research 1992;9(4):464-468. 
18. Neiger R, Ramsey I, O'Connor J, et al. Trilostane treatment of 78 dogs with pituitary-
dependent hyperadrenocorticism. Vet Rec. 2002;150(26):799-804. 
19. Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, 
and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated 
with trilostane. Am J Vet Res. 2002;63(4):506-12. 
20. Braddock JA, Church DB, Robertson ID, et al. Trilostane treatment in dogs with 
pituitary-dependent hyperadrenocorticism. Aust Vet J. 2003;81(10):600-7. 
21. Alenza DP, Arenas C, Lopez ML, et al. Long-term efficacy of trilostane administered 
twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp 
Assoc 2006;42(4):269-76.  
22. Vaughan MA, Feldman EC, Hoar BR, et al. Evaluation of twice-daily, low-dose 
trilostane treatment administered orally in dogs with naturally occurring 
hyperadrenocorticism. J Am Vet Med Assoc. 2008;232(9):1321-8. 
23. Galac S, Buijtels JJ, Mol JA, et al. Effects of trilostane on the pituitary-adrenocortical 
and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism. Vet J. 
2008 [Epub ahead of print]. 
24. Bell R, Neiger R, McGrotty Y, et al. Study of the effects of once daily doses of 
trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic 
hormone in hyperadrenocorticoid dogs. Vet Rec. 2006;159(9):277-81. 
25. Barker EN, Campbell S, Tebb AJ, et al. A comparison of the survival times of dogs 
treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet 
Intern Med 2005;19(6):810-5 
Page 15 of 21 
VCNA-SAP Ramsey August 2009 
26. Clemente M, De Andrés PJ, Arenas C, et al. Comparison of non-selective 
adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-
dependent hyperadrenocorticism. Vet Rec. 2007;161(24):805-9. 
27. Kintzer PP, Peterson ME. Mitotane (o,p-DDD) treatment of 200 dogs with pituitary-
dependent hyperadrenocorticism J Vet Int Med 1991;5(3):182–190.  
28. Semple CG, Thomson JA, Stark AN, et al. Trilostane and the normal hypothalamic-
pituitary-adrenocortical axis. Clin Endocrinol (Oxf). 1982;17(6):569-75. 
29. Feldman EC, Nelson RW. Chapter 6 Canine hyperadrenocorticism (Cushing’s 
Syndrome). In Canine and Feline Endocrinology and Reproduction 3rd Edn. 2004 
Saunders Philadelphia p 252-357 
30. Lorenz MD. Diagnosis and medical management of canine Cushing's syndrome: a 
study of 57 consecutive cases. J Amer Animal Hosp Assoc 1982;18(5):707-716 
31. Dunn KJ, Herrtage ME, Dunn JK. Use of ACTH stimulation tests to monitor the 
treatment of canine hyperadrenocorticism. Vet Rec 1995;137(7):161-165 
32. Chapman PS, Kelly DF, Archer J, et al. Adrenal necrosis in a dog receiving trilostane 
for the treatment of hyperadrenocorticism. J Small Anim Pract. 2004;45(6):307-10. 
33. Ramsey IK, Richardson J, Lenard Z, et al. Persistent isolated hypocortisolism 
following brief treatment with trilostane. Aust Vet J. 2008;86(12):491-5. 
34. Reusch CE, Sieber-Ruckstuhl N, Wenger M, et al. Histological evaluation of the 
adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane. Vet 
Rec. 2007;160(7):219-24.  
35. Witt AL, Neiger R. Adrenocorticotropic hormone levels in dogs with pituitary-
dependent hyperadrenocorticism following trilostane therapy. Vet Rec. 
2004;154(13):399-400. 
36. Mantis P, Lamb CR, Witt AL, et al. Changes in ultrasonographic appearance of 
adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with 
trilostane. Vet Radiol Ultrasound. 2003;44(6):682-5. 
37. Wilbur OM Jr, Riach AR A study of the rold of adrenocorticotrophic hormone 
(ACTH) in the pathogenesis of tubular degeneration of the adrenals Bull John Hopkins 
Hosp 1953;93(5):321-347 
38. Teshima T, Hara Y, Takekoshi S, et al. Trilostane-induced inhibition of cortisol 
secretion results in reduced negative feedback at the hypothalamic-pituitary axis. 
Domest Anim Endocrinol. 2009;36(1):32-44.  
Page 16 of 21 
VCNA-SAP Ramsey August 2009 
39. Eastwood JM, Elwood CM, Hurley KJ. Trilostane treatment of a dog with functional 
adrenocortical neoplasia. J Small Anim Pract. 2003;44(3):126-31. 
40. Benchekroun G, de Fornel-Thibaud P, Lafarge S, et al. Trilostane therapy for 
hyperadrenocorticism in three dogs with adrenocortical metastasis. Vet Rec. 
2008;163(6):190-2. 
41. Machida T, Uchida E, Matsuda K, et al. Aldosterone-, corticosterone- and cortisol-
secreting adrenocortical carcinoma in a dog: case report. J Vet Med Sci. 
2008;70(3):317-20. 
42. Golden DL, Lothrop CD Jr. A retrospective study of aldosterone secretion in normal 
and adrenopathic dogs J Vet Intern Med. 1988;2(3):121-5 
43. Goy-Thollot I, Péchereau D, Kéroack S, et al. Investigation of the role of aldosterone 
in hypertension associated with spontaneous pituitary-dependent 
hyperadrenocorticism in dogs J Small Anim Pract. 2002;43(11):489-92. 
44. Wenger M, Sieber-Ruckstuhl NS, Müller C, et al. Effect of trilostane on serum 
concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-
dependent hyperadrenocorticism. Am J Vet Res. 2004;65(9):1245-50. Erratum in: Am 
J Vet Res. 2004;65(11):1562.  
45. Galac S, Buijtels JJ, Kooistra HS. Urinary Corticoid : Creatinine Ratios in Dogs with 
Pituitary-Dependent Hypercortisolism during Trilostane Treatment J Vet Intern Med. 
2009 (Epub ahead of print)  
46. Randolph JF, Toomey J, Center SA, et al. Use of the urine cortisol-to-creatinine ratio 
for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction 
treatment with mitotane (o,p'-DDD) Am J Vet Res. 1998;59(3):258-61 
47. Angles JM, Feldman EC, Nelson RW, et al. Use of urine cortisol:creatinine ratio 
versus adrenocorticotropic hormone stimulation testing for monitoring mitotane 
treatment of pituitary-dependent hyperadrenocorticism in dogs J Am Vet Med Assoc. 
1997;211(8):1002-4 
48. Guptill L, Scott-Moncrieff JC, Bottoms G, et al. Use of the urine cortisol: creatinine 
ratio to monitor treatment response in dogs with pituitary-dependent 
hyperadrenocorticism.J Am Vet Med Assoc. 1997;210(8):1158-61 
49. McGrotty YL, Arteaga A, Knottenbelt CM, et al. Haptoglobin concentrations in dogs 
undergoing trilostane treatment for hyperadrenocorticism. Vet Clin Pathol. 
2005;34(3):255-8. 
Page 17 of 21 
VCNA-SAP Ramsey August 2009 
50. Arteaga A, Dhand NK, McCann T, et al. Monitoring the response of canine 
hyperadrenocorticism to trilostane treatment assessing acute phase protein 
concentrations" (provisionally accepted J Small Anim Pract)  
51. Peterson ME, Ferguson DC, Kintzer PP, et al. Effects of spontaneous 
hyperadrenocorticism on serum thyroid hormone concentrations in the dog. American 
Journal of Veterinary Research 1984;45(10), 2034-8 
52. Kenefick SJ, Neiger R. The effect of trilostane treatment on circulating thyroid 
hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism. J 
Small Anim Pract. 2008;49(3):139-43. 
53. Ramsey IK, Tebb A., Harris E, et al. Hyperparathyroidism in dogs with 
hyperadrenocorticism J Small Anim Pract 2005;46(11):531-6 
54. Tebb AJ, Arteaga A, Evans H, et al. Canine hyperadrenocorticism: effects of trilostane 
on parathyroid hormone, calcium and phosphate concentrations. J Small Anim Pract. 
2005;46(11):537-42. 
55. Cerundolo R, Lloyd DH, Persechino A, et al. Treatment of canine Alopecia X with 
trilostane. Vet Dermatol. 2004;15(5):285-93.  
56. Leone F, Cerundolo R, Vercelli A, et al. The use of trilostane for the treatment of 
alopecia X in Alaskan malamutes. J Am Anim Hosp Assoc. 2005;41(5):336-42.  
57. McGowan CM, Neiger R. Efficacy of trilostane for the treatment of equine Cushing's 
syndrome. Equine Vet J. 2003;35(4):414-8.  
58. Skelly BJ, Petrus D, Nicholls PK. Use of trilostane for the treatment of pituitary-
dependent hyperadrenocorticism in a cat. J Small Anim Pract. 2003;44(6):269-72. 
59. Neiger R, Witt AL, Noble A, et al. Trilostane therapy for treatment of pituitary-
dependent hyperadrenocorticism in 5 cats. J Vet Intern Med. 2004;18(2):160-4. 
60. Zeugswetter F, Fenske M, Hassan J, et al. Cushing's syndrome in a guinea pig. Vet 
Rec. 2007;160(25):878-80.  
61. Boag AK, Neiger R, Church DB. Trilostane treatment of bilateral adrenal enlargement 
and excessive sex steroid hormone production in a cat. J Small Anim Pract. 
2004;45(5):263-6. 
 
 
Page 18 of 21 
VCNA-SAP Ramsey August 2009 
Diagram 1 
 
Biosynthetic pathways in steriodogenesis. Different tissues of the adrenal gland express 
different enzymes so not all processes occur in all cells. The principle target for the 
competitive inhibitor trilostane is 3β hydroxysteroid dehydrogenase (3β HSD). 
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Figure 1.  Kaplan Meier Survival Curve for both mitotane and trilostane treated animals.      
Dogs alive at the completion of the study and those lost to follow up were censored (indicated 
by a vertical line). Figure reproduced with permission [25]. 
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Table 1 Summary of 6 clinical studies on the use of trilostane in canine hyperadrenocorticism 
Reference [18] [19] [20] [21] [22] [23] 
Country UK Switzerland Australia Spain USA Netherlands 
Study design       
PDH dogs 78 11 30 44 18 63 
ADH dogs 0 0 0 0 4 0 
Starting dose Mean 5.9 mg/kg q24h 
Range 1.8 to 20 
Median 6.3 mg/kg q24h 
Range 3.9 to 9.2 
Median NS 
Range 3 to 12 
Mean 3.1 mg/kg 
q12h (S.D. = 1.3) 
Median 1.4 mg/kg q12h 
Range 0.5 to 2.5 
Median NS 
Range 2-4 mg/kg q24h 
Monitoring 10d, 4, 12, 24w,  then 
every 12-24w 
1,3- 4, 6-7, 12-16, 24-
28w 
10, 30, 90, 180d 7d, 1, 3, 6 months, 
then every 6 months 
1-2, 4-8, 8 -16 w 3w, then every 3w until 
stable 
Target cortisol 
range 
20-250 nmol/l 27-69 nmol/l 25-125 nmol/l 27-135 nmol/l <150 nmol/l 30-190 nmol/l 
Time of 
sampling 
“Most within a few 
hours” 
2 to 6 hours No particular time 4 to 6 hours at 7d, 
then 8 to 12 hours  
3 to 4 hours 2 to 4 hours 
Tablets given 
with food 
Unknown Unknown Unknown NS Yes NS 
Length of 
follow up 
Up to 4 years, 30 dogs 
for more than 24 w 
7 dogs for 1 year, 3 dogs 
for 2 years 
Mean 384 days, range 
170 - 600 days 
Up to 3.5 years 16 weeks Up to 12 weeks 
Study Results       
Dose changes 23 increased and  9 
decreased during study 
4 increased and 3 
decreased during study 
NS 10 increased and 2 
decreased at 1 month 
10 increased 4-8 weeks 
5 increased 8-16 weeks 
22 increased and 4 
decreased during study 
Withdrawals None None None 5 dogs (“economic 
reasons”) 
6 dogs (4 had surgery 
for ADH) 
None 
Final dose Mean  7.3mg/kg q24h 
Range 1.6-27.2 mg/kg 
* 
Median 6.1 mg/kg q24h 
Range 4.1-15.6 mg/kg 
Median 16.7 mg/kg q24h 
Range 5-50 mg/kg 
Mean 3.2 mg/kg 
q12h 
Mean 1.7 mg/kg q12h 
Range 1.1-2.8 mg/kg 
Mean 2.8 mg/kg q24h 
Range 0.8-5.8 mg/kg 
Clinical 
efficacy 
60 (77%) improved by 
4 weeks. 24/39 dogs 
with alopecia improved 
9 (82%) improved after 6 
months of treatment 
30 (100%) improved at 
90 days 
20 stable and 
improved out of 30 
(67%) at 6 months  
15 improved at 4–8 
weeks, 16/18 (89%) at 
8-16 weeks 
60 (95%) improved  
Dogs in target 
cortisol range 
59 (76%) at some time 
during study 
Median above target 
range at 4 re-evaluations 
17 (57%) at 90 days, 23 
(out of 29 (79%) at 180 
days  
26 out of 36 (72%) at 
3 months 
14 out of 16 (87%) at 8-
16 weeks 
100% (definition of 
inclusion) 
Adverse 
effects 
2 dogs died early on 
hypoAC in 2 dogs (1 
died). 13 other minor 
adverse events 
2 minor adverse events One died (unrelated 
cause). No others in first 
6 months, later 4 cases of 
hypoAC 
hypoAC in 11 (25%)  hypoAC in 2 dogs  hypoAC in 5 dogs, 3 
during the study and 2 
after study completed 
Other 
comments 
*Figures not in paper 
but provided by authors 
from original data 
 5 dogs had failed other 
treatments before start of 
study 
Mean survival time 
31 months (95% CI = 
26 to 36) 
3 dogs treated q8h  
Key d = days, w = weeks, NS = not stated in paper 
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